Breast Cancer
A Phase 1/2, Open-label Study of Sacituzumab Govitecan Administered at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer (GS-US-576-7321)
- Details
ClinicalTrials.gov ID:
NCT06926920
Diagnosis Type:
NA
USOR Number:
- Address
,
P: